Navigation Links
Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
Date:11/23/2009

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ --

Dear Isis Supporters and Shareholders,

I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the most successful moments in our history. We are truly at the end of the beginning of creating a unique company with a novel drug discovery platform, which we believe addresses many of the issues haunting the pharmaceutical industry.

Our progress is predicated largely upon the success of our flagship drug, mipomersen. Mipomersen continues to perform well and progress toward commercialization. Isis, our investigators and members of the medical community are very encouraged by the results that were presented at the AHA last week. To get a sense of their support of the drug, I would encourage you to listen to the replay of the mipomersen investigator panel presentation that was conducted during AHA last week. I think you will hear not only their enthusiasm for the drug but their hope that mipomersen will provide a new treatment alternative for their patients at very high risk of cardiovascular disease.

We are disappointed with the reaction on Wall Street to what we believe is very positive news. We believe mipomersen will continue to provide results that speak for themselves. Each success brings us closer to getting mipomersen to the market and making the drug available to patients in need.

Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve the productivity of the pharmaceutical industry. With 19 drugs in development, we have one of the largest and most diverse pipelines in our industry. We know that sick people depend on us. We continue to strive for excellence as we create drugs for the future. We also recognize that behind our successes is the support we receive from you. I would like to personally thank you for that.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
2. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
3. Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
5. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
6. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
7. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
8. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
9. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
10. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
11. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Dallas, TX (PRWEB) September 19, 2014 ... which introduces a traditional Scandinavian style of ... United States. Much like Diet Doc’s medical ... Diet emphasizes cooking and eating good food ... diet also focuses on teaching patients to ...
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... by technological advancements, surgical techniques, and immunosuppressant drugs ... preferred treatment for several chronic diseases related to ... in organ and tissue transplantation have phenomenally revolutionized ... Organ transplant today represents a pivotal medical ...
(Date:9/19/2014)... as Johne,s disease, is caused by the bacterium ... Austria, there is a legal obligation to report ... treatment-resistant diarrhoea and wasting among affected animals. The ... farms. The animals produce less milk, exhibit fertility ... such as udder inflammation. , To date ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 InventHelp, ... clients, an inventor from New York, has created an accessory ... from inclement weather or smoke during transport. This invention ... to a stretcher and remain in place until removed, guarding ... a more comfortable move with protection from irritating smoke or ...
(Date:9/19/2014)... as released a new blog post announcing ... for life insurance. , Clients who have heart disorders ... not require medical examinations. No medical exam life insurance ... minutes. , Some traditional policies (that require medical ... health problems, however the application time is longer and ...
Breaking Medicine News(10 mins):Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Lymphatic fluid used for first time to detect bovine paratuberculosis 2Health News:InventHelp® Client Patents “Patient Protector” – Designed to Protect Patients During Transport 2Health News:No Medical Exam Life Insurance For Clients Who Have Heart Problems! 2
... should reduce the salt intake to avoid high blood pressure and ... g per day//. FSA also stressed that the tinned foods should ... ,Too much of salt is very harmful to humans ... can lead to heart attacks. The amount of salt content is ...
... following ace cricketer Sachin Tendulkar's and several other players complaining ... the sports arena//. ,Tennis elbow, or lateral epicondylitis ... where the outer part of the elbow becomes painful and ... or a direct bang. The problem occurs following overuse of ...
... at high risk of fatal and non-fatal myocardial ... reason for their decreased life expectancy//. There is ... (PPAR-?) could reduce macrovascular complications. Pioglitazone is one ... ,A recent study, published in the October issue ...
... for cardiovascular disease in both men and women, which ... subjects and that 80 percent of all type 2 ... In these patients hyperglycemia per se confers ... of even borderline-high-risk LDL-C signals the need for more ...
... Odors have long been known to be capable of ... effects of essential oils have been acknowledged in folk ... lavender fragrances have been particularly attributed with mood enhancing ... the September issue of the journal Physiology & Behavior, ...
... the benefits of oral ZYVOX for the treatment of ... compared data from 80 health care clinics and compared ... The results show that oral tablets of Linezolid (ZYVOX), ... to health clinics compared to vancomycin. ,This ...
Cached Medicine News:Health News:Tennis elbow not new among cricketers, say experts 2Health News:Aromatherapy: Ambient odors of orange and lavender reduce anxiety 2Health News:Oral use of ZYVOX (Linezolid) is better to Intravenous Vancomycin use for Skin Infections 2
(Date:9/19/2014)... Sept. 19, 2014  Over 200 runners participated in ... Benefit the Radiation Oncology Institute (ROI), hosted by Radiation ... Gate Park in San Francisco.  "Donations ... CEO of Radiation Business Solutions, "but at this ... over $70,000 for the ROI this year. This surpasses ...
(Date:9/19/2014)... 2014  CytRx Corporation (Nasdaq: CYTR ), ... today announced that David J. Haen , Vice ... in the Biotech Industry Conference on Friday, September 26 th ... take place at the Millennium Broadway Hotel in ... live and archived webcast of the presentation will be ...
(Date:9/19/2014)... , September 19, 2014 Reductions ... for many years in people with diabetes type 2 ... long term benefits for the kidneys." Australian ... with type 2 diabetes leads to persistent reductions in ... The global study has found that, five ...
Breaking Medicine Technology:Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... Systems, Inc. (NASDAQ: DCTH ) announced today that ... agreement for the Delcath Hepatic CHEMOSAT ® Delivery system ... Oncologia ---IEO), a premier European cancer treatment and research center ... the Company will provide the IEO with logistics and clinical ...
... Reportlinker.com announces that a new ... its catalogue: , Frost & ... http://www.reportlinker.com/p0490686/Frost--Sullivan-Speaks-Candidly-with-US-Pharmacists.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmacies_and_Drug_Stores ... feedback provided by a healthcare pharmacist ...
Cached Medicine Technology:Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union 2Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union 3Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union 4Frost & Sullivan Speaks Candidly with U.S. Pharmacists 2Frost & Sullivan Speaks Candidly with U.S. Pharmacists 3
Precision that fits in the palm of your hand and measures down to 125 microns, the Pocket Pachymeter is about 8" X 4" x 2" and really does fit in a lab coat pocket or briefcase....
15 segment Vertical Prism Bar provides 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30 PD (Note: 30 PD is on the bar). 4447 xx Vertical Prism Bar....
Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
Sabre 180, 230V, 50Hz is a powerful niche generator....
Medicine Products: